新闻资讯
Phase I Clinical Trial Application of the Central Nervous System Drug ZHB103 Approved by the NMPA
2023.12.25On December 25, 2023, ZHB103 Injection, a new drug in Class 1 of therapeutic biologics originally developed by ZONHONBIO, which has completely independent intellectual property rights at home and abroad, was granted the “Notice of Approval for Clinical Trial of Drugs” by the NMPA. The approved indication is acute ischemic stroke.
< 上一篇
没有了！
下一篇 >
没有了！